TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of patients with treatment associated complications
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Clinical Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in The Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Assessment Scale for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Skills Improvement System
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Goal attainment scaling
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Victimization
Endpoint domain: Adverse events/effects
Primary endpoint: AFB1-lysine Adduct (pg/mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type 3-5 Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year change in prevalence of biomarkers of chronic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year change in micronutrient status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiological growth on suture tread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative pain in the operated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive inotropic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-related barriers to management of cancer pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in total physical exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Patients With Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing at D6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety and tolerability of dutogliptin
Endpoint domain: Adverse events/effects
Primary endpoint: Serum total adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence (changes)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Somnolence (changes)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Perceived Competence (changes)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cocaine Craving as Measured on the Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcohol Craving as Measured by the Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Markers of Oxidative Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of Analgesic Medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PTSD Checklist for DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted Mean Change in HbA1c Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Fugl-Meyer Assessment of Upper Extremities motor recovery after stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid consumption (morphine mg equivalents)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum fall of FEV1 in exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the IKDC Subjective Knee Evaluation Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Visual Analog Scale (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in performance scores on computerized cognitive remediation tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnosis of adrenal mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: International Index of Erectile Function (IIEF) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prediction of gastric cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response (Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Status of global hypoxia within the prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor vasculature and metabolism within the prostate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of prostate and normal tissue hypoxia with clinical outcomes after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on laparoscopic skills assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan Hand Outcomes Questionnaire (MHOQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Pancreatic Cancer Cases with Gabapentin Exposure
Endpoint domain: Mortality/survival
Primary endpoint: Number of Renal Cancer Cases with Gabapentin Exposure
Endpoint domain: Mortality/survival
Primary endpoint: Degree of tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Degree of cooperation during inhalation anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Respiratory event index (REI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Augmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Culture positivity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Cardiovascular Death, Target Vessel Myocardial Infarction (TV-MI) or Clinically-Driven Target Lesion Revascularization (CD-TLR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of findings related to gluten sensitive enteropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in lactate transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glycated hemoglobin% (HbA1c%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative risk of infant infection
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate without any recurrence of AF
Endpoint domain: Mortality/survival
Primary endpoint: 2-Year Progression Free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of chronic grade 2 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rate of myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of hospitalization due to congestive heart failure (CHF)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of transplant related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of the need for rescue autologous bone marrow transplant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of clinically detectable malignancy and/or abnormal clonal dominance assessed as related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Hematology/Chemistry/Urinalysis Laboratories of Baseline CTCAE Grade ≤2 That Shifted to a Maximum CTCAE Grade 3 or 4
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Partial Response (PR) and Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue free laxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rapid Cognitive Screen Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retention of laminate veneers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fracture of laminate veneers
Endpoint domain: Adverse events/effects
Primary endpoint: Marginal adaptation of laminate veneers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Development of Posterior capsule opacification
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to exercise regimen
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recanalization rate of occluded target vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Duration of ERCP treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in axis orientation of the TICL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC [0-infinity]) of Plasma Gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Plasma Gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Half-life (t1/2) of Plasma Gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incremental area under curve (iAUC) for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Respiratory Deteriorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Hemodynamic Deteriorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ACQ (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difficulties completing duties at work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum tolerance dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumoral Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: p-CLE findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Interrater reliability of the ASA classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Resource Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ratio of omega-3 to omega-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Catheter-related Venous Thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in P2Y12% inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best corrected distant visual acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Severe/Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of infection and inflammation
Endpoint domain: Adverse events/effects
Primary endpoint: Change of speech and acoustic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening adherence at 6 months by medical record review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall colorectal cancer screening adherence at 12 months by medical record review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening decision stage at 6-months (Stool Blood Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLP-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cardiovascular dysfunction markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respond to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Warwick-Edinburgh Mental Wellbeing Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinically Significant Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Pain Assessed by Numerical Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration AUC(0-T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve extrapolated to infinity AUC (INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of apnea and/or bradycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Sum of pain intensity differences over 24 hours (SPID 24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle peak power during push-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Dysexecutive Syndrome Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peripheral endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potentially Clinically Significant Abnormality (PCSA): Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Abnormality: Clinical Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Abnormality: Urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glucose response measured as incremental area under the curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Star Excursion Balance Test of the Uninvolved Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric hip strength of the Uninvolved Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbopelvic stability of the Uninvolved Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptance/usage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: accessibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disease progression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filter retrieval rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: >80% Inhibition of FLT3 Phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay in Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: DIAPASON questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastrointestinal peptide release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self-control as the learned resourcefulness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year Event Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Postoperative Sore Throat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Oral Intake Scale (FOIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Clinical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid artery restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Who Experienced Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: GI symptoms secondary to GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Skin symptoms secondary to GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weight distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical opiate withdrawal scale (COWS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between electronic and paper pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CT imaging features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTA imaging markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MR imaging markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of critical, serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: H/M reflex ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sputum Percent Neutrophils (PMNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Slowing the progression of carotid IMT and plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achieving CV risk factor target goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Count of Participants Not Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Drug Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: PSA Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Confirmed Social Responsiveness Scale (SRS) Responders
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 42-day-cumulative Incidence of Proven or Probable Invasive Fungal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Fat fraction in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to evidence of adherence failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunological Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events by toxicity grade and relationship to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Aerobic capacity (VO2 max in ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rest/Max Heart rate in beat/min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic and diastolic blood pressure in mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antibody response to antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 5D-ASC profile total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: non-progression rate
Endpoint domain: Mortality/survival
Primary endpoint: Wolf Motor Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Byl-Cheney-Boczai Sensory Discriminator Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graphesthesia (modified sub test of sensory integration praxis test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes